

# Christopher L Bowlus

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4266174/christopher-l-bowlus-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186  
papers

8,073  
citations

48  
h-index

84  
g-index

225  
ext. papers

9,607  
ext. citations

7.5  
avg, IF

5.94  
L-index

#	Paper	IF	Citations
186	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
185	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , <b>2021</b> , 73, 1105-1116	11.2	2
184	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1248-1257	6.9	6
183	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2021</b> ,	7.9	7
182	Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. <i>Free Radical Biology and Medicine</i> , <b>2021</b> , 172, 490-502	7.8	4
181	Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
180	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. <i>Gastroenterology</i> , <b>2021</b> , 161, 1764-1775.e5	13.3	0
179	Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans. <i>Clinical Immunology</i> , <b>2021</b> , 230, 108825	9	0
178	Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	1
177	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. <i>Hepatology Communications</i> , <b>2021</b> , 5, 478-490	6	7
176	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S464-S465	13.4	3
175	Electronic health record alerts enhance mass screening for chronic hepatitis B. <i>Scientific Reports</i> , <b>2020</b> , 10, 19153	4.9	3
174	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. <i>Journal of Autoimmunity</i> , <b>2020</b> , 113, 102503	15.5	4
173	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 94-101	13.4	57
172	The use of biologics in the treatment of autoimmune liver disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 385-398	5.9	2
171	Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 262-270	0.7	6
170	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. <i>Clinical Liver Disease</i> , <b>2020</b> , 15, 1-2	2.2	6

169	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2295-2304.e2	6.9	5
168	Primary Biliary Cholangitis: A Brief Overview. <i>Clinical Liver Disease</i> , <b>2020</b> , 15, 100-104	2.2	3
167	S0984 Long-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, S501-S502	0.7	
166	Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases. <i>Gastroenterology and Hepatology</i> , <b>2020</b> , 16, 31-38	0.7	
165	Primary Biliary Cholangitis <b>2020</b> , 335-357		0
164	Diagnostic Liver Immunology <b>2020</b> , 139-150		
163	Healthcare Disparities Identified Between Hmong and Other Asian Origin Groups Living with Chronic Hepatitis B Infection in Sacramento County 2014-2017. <i>Journal of Community Health</i> , <b>2020</b> , 45, 412-418	4	1
162	Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2020</b> , 59, 175-194	12.3	10
161	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1170-1178.e6	6.9	39
160	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> , <b>2020</b> , 2, 100060	10.3	6
159	Role of Antinuclear Antibodies in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1604-1606	0.7	1
158	Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis. <i>Clinical Epidemiology</i> , <b>2020</b> , 12, 1261-1267	5.9	
157	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 179-187.e6	6.9	24
156	Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2020</b> , 58, 134-149	12.3	17
155	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , <b>2019</b> , 105, 102328	15.5	45
154	FRI-037-Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e400	13.4	2
153	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , <b>2019</b> , 70, 788-801	11.2	101
152	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e1-e2	13.4	10

151	Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. <i>Liver Research</i> , <b>2019</b> , 3, 118-127	4.1	4
150	Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. <i>Journal of Autoimmunity</i> , <b>2019</b> , 101, 26-34	15.5	25
149	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 445-453	18.8	73
148	Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1372-1378	6.9	9
147	Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. <i>Epigenetics and Chromatin</i> , <b>2019</b> , 12, 10	5.8	23
146	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , <b>2019</b> , 3, 365-381	6	30
145	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , <b>2019</b> , 69, 394-419	11.2	224
144	FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e390-e391	13.4	2
143	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2416-2422	6.9	31
142	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> , <b>2019</b> , 69, 684-698	11.2	71
141	RAR1 acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells. <i>FASEB Journal</i> , <b>2019</b> , 33, 2314-2326	0.9	11
140	A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. <i>Hepatology Communications</i> , <b>2018</b> , 2, 484-491	6	6
139	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 591-593	6.9	10
138	Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1342-1350.e1	6.9	40
137	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 54, 282-294	12.3	26
136	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 368-377	13.4	16
135	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1333-1341.e6	6.9	26
134	Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose ranging phase 2 study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S105-S106	13.4	9

133	Primary biliary cholangitis: Diagnosis and treatment. <i>Liver Research</i> , <b>2018</b> , 2, 81-86	4.1	2
132	Electronic Medical Alerts Increase Screening for Chronic Hepatitis B: A Randomized, Double-Blind, Controlled Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 1352-1357	4	9
131	PC.01.8 THE AESOP TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, e67	3.3	9
130	Community-Based Services to Improve Testing and Linkage to Care Among Non-U.S.-Born Persons with Chronic Hepatitis B Virus Infection - Three U.S. Programs, October 2014-September 2017. <i>Morbidity and Mortality Weekly Report</i> , <b>2018</b> , 67, 541-546	31.7	27
129	Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 154-163	0.7	6
128	Primary and Secondary Sclerosing Cholangitis <b>2018</b> , 626-647.e6		
127	Scratching the surface of cholestatic itch treatments. <i>Hepatology</i> , <b>2018</b> , 67, 2045-2048	11.2	4
126	Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. <i>Hepatology</i> , <b>2018</b> , 68, 155-165	11.2	14
125	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , <b>2018</b> , 67, 1517-1524	19.2	28
124	Common Variable Immunodeficiency and Liver Involvement. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 55, 340-351	12.3	32
123	Etiopathogenesis of autoimmune hepatitis. <i>Journal of Autoimmunity</i> , <b>2018</b> , 95, 133-143	15.5	62
122	Current Treatment Options for Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , <b>2018</b> , 22, 481-500	4.6	4
121	558 - International Experience of Vedolizumab in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2018</b> , 154, S-1097	13.3	2
120	The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. <i>Cellular and Molecular Immunology</i> , <b>2017</b> , 14, 276-284	15.4	37
119	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
118	Geoeidemiology and changing mortality in primary biliary cholangitis. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 655-662	6.9	12
117	Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics. <i>Hepatology</i> , <b>2017</b> , 66, 885-895	11.2	21
116	Primary Biliary Cholangitis: Its Science and Practice <b>2017</b> , 129-182		

115	Human $\beta$ -Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , <b>2017</b> , 8, e80	4.2	3
114	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , <b>2017</b> , 49, 269-273	36.3	140
113	Seladelpar (MBX-8025), a selective PPAR- $\delta$ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 716-726	18.8	81
112	The evolution of natural history of primary sclerosing cholangitis. <i>Current Opinion in Gastroenterology</i> , <b>2017</b> , 33, 71-77	3	37
111	The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2017</b> , 52, 424-435	12.3	19
110	Primary sclerosing cholangitis: A review and update. <i>Liver Research</i> , <b>2017</b> , 1, 221-230	4.1	19
109	Epidemiology and Natural History of Primary Sclerosing Cholangitis <b>2017</b> , 1-11		1
108	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 631-43	59.2	574
107	Management of symptom complexes in primary biliary cholangitis. <i>Current Opinion in Gastroenterology</i> , <b>2016</b> , 32, 204-9	3	5
106	Evaluation of indeterminate biliary strictures. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 28-37	24.2	64
105	Proposed therapies in primary biliary cholangitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 371-382	4.2	8
104	Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches. <i>Clinics in Liver Disease</i> , <b>2016</b> , 20, 67-77	4.6	20
103	Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 8584-8595	5.6	36
102	Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. <i>Hepatic Medicine: Evidence and Research</i> , <b>2016</b> , 8, 89-95	3.4	27
101	Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2016</b> , 22, S3-S15	1.9	17
100	Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice. <i>Clinical and Experimental Immunology</i> , <b>2016</b> , 185, 154-64	6.2	10
99	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , <b>2016</b> , 185, 61-71	6.2	59
98	Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 795-800	13.6	27

97	Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 2776-2783	4	8
96	Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. <i>Liver International</i> , <b>2015</b> , 35, 642-51	7.9	48
95	Capsule commentary on Mukhtar et al., Assessment of HBV preventive services in a medically underserved Asian and Pacific Islander population using provider and patient data. <i>Journal of General Internal Medicine</i> , <b>2015</b> , 30, 866	4	
94	Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 48, 132-41	12.3	39
93	Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 180, 371-82	6.2	13
92	New therapies for primary biliary cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 48, 263-72	12.3	28
91	Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 633-43	4	25
90	IL-35 and Autoimmunity: a Comprehensive Perspective. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 49, 327-32	12.3	61
89	Primary sclerosing cholangitis: One disease or several?. <i>Clinical Liver Disease</i> , <b>2014</b> , 3, 34-37	2.2	1
88	Diagnosis and classification of primary sclerosing cholangitis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 445-50	13.6	42
87	The diagnosis of primary biliary cirrhosis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 441-4	13.6	101
86	O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES [AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S525-S526	13.4	28
85	Obeticholic acid for the treatment of primary biliary cirrhosis. <i>Expert Opinion on Orphan Drugs</i> , <b>2014</b> , 2, 1351-1358	1.1	2
84	p53 Autoantibodies <b>2014</b> , 289-294		
83	Cytoskeletal Autoantibodies/Antiactin Antibodies <b>2014</b> , 311-317		1
82	Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. <i>Hepatology</i> , <b>2014</b> , 60, 1708-1716	11.2	59
81	IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. <i>Hepatology</i> , <b>2014</b> , 59, 1944-53	11.2	137
80	Diagnostic Liver Immunology <b>2014</b> , 45-53		

79	Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. <i>Hepatology</i> , <b>2013</b> , 57, 1498-508	11.2	46
78	Iron Metabolism and Related Disorders <b>2013</b> , 1-41		3
77	Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. <i>Journal of Immunology</i> , <b>2013</b> , 191, 2126-33	5.3	27
76	Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 807-14	4	36
75	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , <b>2013</b> , 45, 670-5	36.3	267
74	Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 782-91	4	47
73	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 174, 364-71	6.2	35
72	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. <i>Hepatology</i> , <b>2012</b> , 55, 512-21	11.2	107
71	Immunological orchestration of liver fibrosis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2012</b> , 43, 220-9	12.3	20
70	The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2012</b> , 43, 230-41	12.3	23
69	Primary sclerosing cholangitis etiopathogenesis and clinical management. <i>Frontiers in Bioscience - Elite</i> , <b>2012</b> , E4, 1683-1705	1.6	11
68	Interim report of a randomized cross-over study comparing clinical performance of novice trainee endoscopists using conventional air insufflation versus warm water infusion colonoscopy. <i>Journal of Interventional Gastroenterology</i> , <b>2012</b> , 2, 135-139		5
67	Primary sclerosing cholangitis: etiopathogenesis and clinical management. <i>Frontiers in Bioscience - Elite</i> , <b>2012</b> , 4, 1683-705	1.6	10
66	In situ mass spectrometry of autoimmune liver diseases. <i>Cellular and Molecular Immunology</i> , <b>2011</b> , 8, 237-42	15.4	10
65	T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. <i>Journal of Autoimmunity</i> , <b>2011</b> , 37, 71-8	15.5	24
64	Primary biliary cirrhosis. <i>Lancet, The</i> , <b>2011</b> , 377, 1600-9	40	220
63	S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2011</b> , 35, 1960-5	3.7	50
62	Cutting edge issues in primary sclerosing cholangitis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2011</b> , 41, 139-50	12.3	19



61	The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 83	3	64
60	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. <i>Hepatology</i> , <b>2011</b> , 54, 196-203	11.2	48
59	Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. <i>Hepatology</i> , <b>2011</b> , 54, 1293-302	11.2	42
58	Prevalence of hepatitis B surface antigen in US-born and foreign-born Asian/Pacific Islander college students. <i>Journal of American College Health</i> , <b>2010</b> , 59, 37-41	2.2	6
57	Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 551-7	13.4	49
56	The geoeidemiology of autoimmune intestinal diseases. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, A372-8	13.6	88
55	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. <i>Hepatology</i> , <b>2010</b> , 52, 987-98	11.2	154
54	Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. <i>Liver Transplantation</i> , <b>2010</b> , 16, 1324-30	4.5	50
53	The immunobiology of primary sclerosing cholangitis. <i>Seminars in Immunopathology</i> , <b>2009</b> , 31, 383-97	12	67
52	Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. <i>Seminars in Immunopathology</i> , <b>2009</b> , 31, 309-22	12	72
51	B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. <i>Gastroenterology</i> , <b>2009</b> , 136, 1037-47	13.3	69
50	Anti-mitochondrial antibody-negative primary biliary cirrhosis. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 173-85, ix	4.6	27
49	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 275-86	2.5	591
48	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 275-286	2.5	217
47	Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. <i>Pediatric Hematology and Oncology</i> , <b>2007</b> , 24, 237-43	1.7	28
46	Quality of life and everyday activities in patients with primary biliary cirrhosis. <i>Hepatology</i> , <b>2007</b> , 46, 1836-43	14.3	24
45	De novo nonalcoholic fatty liver disease after liver transplantation. <i>Liver Transplantation</i> , <b>2007</b> , 13, 844-7	4.5	140
44	The potentiating and protective effects of ascorbate on oxidative stress depend upon the concentration of dietary iron fed C3H mice. <i>Journal of Nutritional Biochemistry</i> , <b>2007</b> , 18, 272-8	6.3	8

43	Effect of penicillamine and zinc on iron metabolism in Wilson's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 1495-500	2.4	20
42	Non-alcoholic fatty liver disease: the new epidemic and the need for novel nutritional approaches. <i>Journal of Medicinal Food</i> , <b>2007</b> , 10, 563-5	2.8	9
41	CYTOSKELETAL AUTOANTIBODIES/ANTI-ACTIN ANTIBODIES <b>2007</b> , 309-316		1
40	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 139-53	3.5	235
39	Tumor Immunology <b>2007</b> , 137-149		
38	T cell immunity and graft-versus-host disease (GVHD). <i>Autoimmunity Reviews</i> , <b>2006</b> , 5, 1-9	13.6	50
37	Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. <i>Hepatology</i> , <b>2006</b> , 43, 729-37	11.2	244
36	Gene expression by PBMC in primary sclerosing cholangitis: evidence for dysregulation of immune mediated genes. <i>Clinical and Developmental Immunology</i> , <b>2006</b> , 13, 265-71		13
35	Revisiting hereditary hemochromatosis: current concepts and progress. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 391-9	2.4	46
34	IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2006</b> , 27, 50-3	15.5	147
33	Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 704-10	13.4	20
32	Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. <i>Journal of Gastroenterology</i> , <b>2006</b> , 41, 954-61	6.9	39
31	Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. <i>Journal of Gastroenterology</i> , <b>2006</b> , 41, 1053-63	6.9	46
30	Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 390-6	6.9	70
29	An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction. <i>Digestive and Liver Disease</i> , <b>2005</b> , 37, 206-10	3.3	4
28	The immunobiology of primary sclerosing cholangitis. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 137-43	13.6	61
27	T cell immunity in autoimmune hepatitis. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 315-21	13.6	89
26	Transforming growth factor beta (TGF-beta) and autoimmunity. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 450-9	13.6	81

25	Prss16 is not required for T-cell development. <i>Molecular and Cellular Biology</i> , <b>2005</b> , 25, 789-96	4.8	10
24	Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. <i>Journal of Clinical Gastroenterology</i> , <b>2005</b> , 39, 71-4	3	56
23	Ascorbic acid does not increase the oxidative stress induced by dietary iron in C3H mice. <i>Journal of Nutrition</i> , <b>2004</b> , 134, 435-8	4.1	15
22	Transcription profile of <i>Helicobacter pylori</i> in the human stomach reflects its physiology in vivo. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 946-56	7	26
21	Obesity in BSB mice is correlated with expression of genes for iron homeostasis and leptin. <i>Obesity</i> , <b>2004</b> , 12, 191-204		20
20	DMT1 and FPN1 expression during infancy: developmental regulation of iron absorption. <i>American Journal of Physiology - Renal Physiology</i> , <b>2003</b> , 285, G1153-61	5.1	48
19	Iron supplementation during infancy--effects on expression of iron transporters, iron absorption, and iron utilization in rat pups. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 78, 1203-11	7	55
18	Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. <i>Hepatology</i> , <b>2003</b> , 38, 1018-1025	11.2	48
17	Effect of iron treatment on nickel absorption and gene expression of the divalent metal transporter (DMT1) by human intestinal Caco-2 cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2003</b> , 92, 121-4		33
16	Discussion of the role of hemochromatosis susceptibility gene mutation in protecting against iron deficiency in celiac disease. <i>Gastroenterology</i> , <b>2003</b> , 124, 1562-3; author reply 1564	13.3	1
15	Ascorbic acid reduces the frequency of iron induced micronuclei in bone marrow cells of mice. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , <b>2003</b> , 542, 99-103	3	17
14	The role of iron in T cell development and autoimmunity. <i>Autoimmunity Reviews</i> , <b>2003</b> , 2, 73-8	13.6	70
13	Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. <i>Hepatology</i> , <b>2003</b> , 38, 1018-25	11.2	15
12	Analysis of the IDDM candidate gene Prss16 in NOD and NON mice. <i>Autoimmunity</i> , <b>2002</b> , 9, 183-6		4
11	Polymorphisms in the gene encoding thymus-specific serine protease in the extended HLA complex: a potential candidate gene for autoimmune and HLA-associated diseases. <i>Genes and Immunity</i> , <b>2002</b> , 3, 306-12	4.4	16
10	Expression, genomic structure and mapping of the thymus specific protease prss16: a candidate gene for insulin dependent diabetes mellitus susceptibility. <i>Journal of Autoimmunity</i> , <b>2002</b> , 18, 311-6	15.5	11
9	DMT1 gene expression and cadmium absorption in human absorptive enterocytes. <i>Toxicology Letters</i> , <b>2001</b> , 122, 171-7	4.4	123
8	Costs of hepatitis C. <i>Archives of Internal Medicine</i> , <b>2001</b> , 161, 2231-7		76

7	Functional and molecular responses of human intestinal Caco-2 cells to iron treatment. <i>American Journal of Clinical Nutrition</i> , <b>2000</b> , 72, 770-5	7	54
6	Granular cells as a marker of early amiodarone hepatotoxicity. <i>Journal of Clinical Gastroenterology</i> , <b>2000</b> , 31, 241-3	3	7
5	Cloning of a novel MHC-encoded serine peptidase highly expressed by cortical epithelial cells of the thymus. <i>Cellular Immunology</i> , <b>1999</b> , 196, 80-6	4.4	51
4	Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization. <i>Biological Psychiatry</i> , <b>1998</b> , 44, 659-66	7.9	40
3	A transcription map of the major histocompatibility complex (MHC) class I region. <i>Genomics</i> , <b>1996</b> , 36, 70-85	4.3	45
2	FISH-Mapped CEPH YACs spanning 0 to 46 cM on human chromosome 6. <i>Genomics</i> , <b>1996</b> , 36, 104-11	4.3	11
1	Cloning and analysis of the promotor region of the human fibronectin gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1987</b> , 84, 1876-80	11.5	91